Recruiting studies: Advanced Solid Tumors With Homozygous Mtap Deletion

Studies currently listed as recruiting on the public registry for this search term. Each page explains the study in plain language, with locations and the study team's contact details. Clinicians: generate a printable list for your patient →

A Study to Assess Safety, Tolerability and Drug Levels of Navlimetostat (BMS-986504) in Participants With Advanced Solid
Phase 1 · 12 location(s) · Bristol-Myers Squibb · NCT07077434 Study of ISM3412 in Participants With Locally Advanced/Metastatic Solid Tumors
Phase 1/Phase 2 · 10 location(s) · InSilico Medicine Hong Kong Limited · NCT06414460 Phase 1 Study of MRTX1719 in Solid Tumors With MTAP Deletion
Phase 1 · 25 location(s) · Bristol-Myers Squibb · NCT05245500 A Phase I Study of SY-9453 in Patients With Advanced Solid Tumors
Phase 1 · 1 location(s) · Shouyao Holdings (Beijing) Co. LTD · NCT07469982 A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors
Phase 1 · 16 location(s) · IDEAYA Biosciences · NCT07277413 A Study to Evaluate the Mass Balance, Metabolism, Elimination, and Drug Levels of [14C]-BMS-986504 (MRTX1719) in Partici
Phase 1 · 3 location(s) · Bristol-Myers Squibb · NCT06672523

Look up another condition

Patient organization or foundation? You can brand this page for your community — your logo, your resources, same honest registry data, kept current daily. Ask about branding →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.